Anti Diabetic

Jump to

See FY17 margin at 17% with downside pressure: Alkem Labs

The company will work towards increasing volumes in the gastro-intestinal, anti-diabetic and cardio segments, among others, to overcome margin pressures due to industry headwinds, says Prabhat Agrawal, CEO of Alkem Laboratories.
Nod by international regulators key for Cadila: Dandekar

Getting an approval for the product for all the four areas i.e, ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis is a big achievement for Cadila said Vikas Dandekar.
Aarti Drugs expects over Rs 700cr revenue in FY12

Harshit Savla, MD of Aarti Drugs, in an interview with CNBC-TV18’s Gautam Broker and Latha Venkatesh, spoke about the recent happenings in his company and the road ahead.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Anti Diabetic

See FY17 margin at 17% with downside pressure: Alkem Labs

Nod by international regulators key for Cadila: Dandekar

Aarti Drugs expects over Rs 700cr revenue in FY12